Research programme: angiogenesis inhibitors - Boehringer Ingelheim

Alternative Names: BIBF-1000

Latest Information Update: 04 Nov 2017

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Boehringer Ingelheim; Boehringer Ingelheim Pharma KG
Class Indoles
Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor-2 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Austria (PO)
04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Germany (PO)
16 Jan 2013 Preclinical development is ongoing in Austria and Germany

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com